Nontuberculous mycobacterial infections in children with inborn errors of the immune system

Summary Severe mycobacterial disease is mostly confined to patients who are immunocompromized either by acquired or inherited causes. One such genetic disorder is Mendelian Susceptibility to Mycobacterial Disease (MSMD), a hot topic within the field of primary immunodeficiency. This single gene diso...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infection 2014-01, Vol.68, p.S134-S150
Hauptverfasser: Haverkamp, Margje H, van de Vosse, Esther, van Dissel, Jaap T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S150
container_issue
container_start_page S134
container_title The Journal of infection
container_volume 68
creator Haverkamp, Margje H
van de Vosse, Esther
van Dissel, Jaap T
description Summary Severe mycobacterial disease is mostly confined to patients who are immunocompromized either by acquired or inherited causes. One such genetic disorder is Mendelian Susceptibility to Mycobacterial Disease (MSMD), a hot topic within the field of primary immunodeficiency. This single gene disorder is characterized by isolated infection with mycobacteria or Salmonella due to a defect in the type-1 cytokine response. In the last two decades, ten genes have been labeled as causing MSMD when they harbor germline mutations, namely IL12B , IL12RB1 , IFNGR1 , IFNGR2 , STAT1 , IKBKG , CYBB , TYK2 , IRF8 and ISG15 . The mutations lead to either insufficient production of IFN-γ, or to an insufficient response to the cytokine. Current treatment options include recombinant IFN-γ and hematologic stem cell transplantation (HSCT). In the future, gene therapy, antisense-mediated exon skipping and chemical intervention in glycosylation problems may become successful alternatives. Furthermore, it is likely that many new candidate genes and pathways crucial for mycobacterial immunity will be identified.
doi_str_mv 10.1016/j.jinf.2013.09.024
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1540221039</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0163445313002910</els_id><sourcerecordid>1490730862</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-5c2df6e4fd7c679c92806b8979daca50c9951b9a40e927d90ce1110041cf691c3</originalsourceid><addsrcrecordid>eNqNkk2L1TAUhoMoznX0D7iQLt20nny0uQERZPALBmehrlyE9vSUm9omY9Iq999Pyh1duHBmERLCc1445zmMPedQceDNq7EanR8qAVxWYCoQ6gHb8VqKUmglHrJdhmSpVC3P2JOURgAw0jSP2ZlQnJu9aHbs--fgl7WjiOsU1lTMRwxdiwtF105FjidcXPApPws8uKmP5Ivfbjnkjy5EX1CMIaYiDMVyoMLN8-qpSMe00PyUPRraKdGz2_ucfXv_7uvFx_Ly6sOni7eXJSqtl7JG0Q8NqaHX2GiDRuyh6fZGm77FtgY0puadaRWQEbo3gMQ5B1Ach8ZwlOfs5Sn3OoafK6XFzi4hTVPrKfdkea1ACA7S3AOFWqp89N2oMqAl7BuRUXFCMYaUIg32Orq5jUfLwW6q7Gg3VXZTZcHYrCoXvbjNX7uZ-r8lf9xk4PUJoDy7X46iTejII_UuZiu2D-7_-W_-KcfJeYft9IOOlMawRp-tWG6TsGC_bMuy7QqXAMLkad0Av8C5tw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490730862</pqid></control><display><type>article</type><title>Nontuberculous mycobacterial infections in children with inborn errors of the immune system</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Haverkamp, Margje H ; van de Vosse, Esther ; van Dissel, Jaap T</creator><creatorcontrib>Haverkamp, Margje H ; van de Vosse, Esther ; van Dissel, Jaap T</creatorcontrib><description>Summary Severe mycobacterial disease is mostly confined to patients who are immunocompromized either by acquired or inherited causes. One such genetic disorder is Mendelian Susceptibility to Mycobacterial Disease (MSMD), a hot topic within the field of primary immunodeficiency. This single gene disorder is characterized by isolated infection with mycobacteria or Salmonella due to a defect in the type-1 cytokine response. In the last two decades, ten genes have been labeled as causing MSMD when they harbor germline mutations, namely IL12B , IL12RB1 , IFNGR1 , IFNGR2 , STAT1 , IKBKG , CYBB , TYK2 , IRF8 and ISG15 . The mutations lead to either insufficient production of IFN-γ, or to an insufficient response to the cytokine. Current treatment options include recombinant IFN-γ and hematologic stem cell transplantation (HSCT). In the future, gene therapy, antisense-mediated exon skipping and chemical intervention in glycosylation problems may become successful alternatives. Furthermore, it is likely that many new candidate genes and pathways crucial for mycobacterial immunity will be identified.</description><identifier>ISSN: 0163-4453</identifier><identifier>EISSN: 1532-2742</identifier><identifier>DOI: 10.1016/j.jinf.2013.09.024</identifier><identifier>PMID: 24119826</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Child ; Child, Preschool ; Children ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunotherapy - methods ; Indexing in process ; Infectious Disease ; Interferon-gamma - therapeutic use ; MSMD ; Mutation ; Mycobacterial infection ; Mycobacterium ; Mycobacterium Infections, Nontuberculous - complications ; Mycobacterium Infections, Nontuberculous - epidemiology ; Mycobacterium Infections, Nontuberculous - genetics ; Mycobacterium Infections, Nontuberculous - immunology ; Mycobacterium Infections, Nontuberculous - therapy ; Nontuberculous Mycobacteria - isolation &amp; purification ; Salmonella ; Salmonella - isolation &amp; purification ; Salmonella Infections - epidemiology ; Salmonella Infections - genetics ; Salmonella Infections - immunology ; Salmonella Infections - therapy</subject><ispartof>The Journal of infection, 2014-01, Vol.68, p.S134-S150</ispartof><rights>The British Infection Association</rights><rights>2013 The British Infection Association</rights><rights>Copyright © 2013 The British Infection Association. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-5c2df6e4fd7c679c92806b8979daca50c9951b9a40e927d90ce1110041cf691c3</citedby><cites>FETCH-LOGICAL-c477t-5c2df6e4fd7c679c92806b8979daca50c9951b9a40e927d90ce1110041cf691c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jinf.2013.09.024$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24119826$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haverkamp, Margje H</creatorcontrib><creatorcontrib>van de Vosse, Esther</creatorcontrib><creatorcontrib>van Dissel, Jaap T</creatorcontrib><title>Nontuberculous mycobacterial infections in children with inborn errors of the immune system</title><title>The Journal of infection</title><addtitle>J Infect</addtitle><description>Summary Severe mycobacterial disease is mostly confined to patients who are immunocompromized either by acquired or inherited causes. One such genetic disorder is Mendelian Susceptibility to Mycobacterial Disease (MSMD), a hot topic within the field of primary immunodeficiency. This single gene disorder is characterized by isolated infection with mycobacteria or Salmonella due to a defect in the type-1 cytokine response. In the last two decades, ten genes have been labeled as causing MSMD when they harbor germline mutations, namely IL12B , IL12RB1 , IFNGR1 , IFNGR2 , STAT1 , IKBKG , CYBB , TYK2 , IRF8 and ISG15 . The mutations lead to either insufficient production of IFN-γ, or to an insufficient response to the cytokine. Current treatment options include recombinant IFN-γ and hematologic stem cell transplantation (HSCT). In the future, gene therapy, antisense-mediated exon skipping and chemical intervention in glycosylation problems may become successful alternatives. Furthermore, it is likely that many new candidate genes and pathways crucial for mycobacterial immunity will be identified.</description><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Immunotherapy - methods</subject><subject>Indexing in process</subject><subject>Infectious Disease</subject><subject>Interferon-gamma - therapeutic use</subject><subject>MSMD</subject><subject>Mutation</subject><subject>Mycobacterial infection</subject><subject>Mycobacterium</subject><subject>Mycobacterium Infections, Nontuberculous - complications</subject><subject>Mycobacterium Infections, Nontuberculous - epidemiology</subject><subject>Mycobacterium Infections, Nontuberculous - genetics</subject><subject>Mycobacterium Infections, Nontuberculous - immunology</subject><subject>Mycobacterium Infections, Nontuberculous - therapy</subject><subject>Nontuberculous Mycobacteria - isolation &amp; purification</subject><subject>Salmonella</subject><subject>Salmonella - isolation &amp; purification</subject><subject>Salmonella Infections - epidemiology</subject><subject>Salmonella Infections - genetics</subject><subject>Salmonella Infections - immunology</subject><subject>Salmonella Infections - therapy</subject><issn>0163-4453</issn><issn>1532-2742</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk2L1TAUhoMoznX0D7iQLt20nny0uQERZPALBmehrlyE9vSUm9omY9Iq999Pyh1duHBmERLCc1445zmMPedQceDNq7EanR8qAVxWYCoQ6gHb8VqKUmglHrJdhmSpVC3P2JOURgAw0jSP2ZlQnJu9aHbs--fgl7WjiOsU1lTMRwxdiwtF105FjidcXPApPws8uKmP5Ivfbjnkjy5EX1CMIaYiDMVyoMLN8-qpSMe00PyUPRraKdGz2_ucfXv_7uvFx_Ly6sOni7eXJSqtl7JG0Q8NqaHX2GiDRuyh6fZGm77FtgY0puadaRWQEbo3gMQ5B1Ach8ZwlOfs5Sn3OoafK6XFzi4hTVPrKfdkea1ACA7S3AOFWqp89N2oMqAl7BuRUXFCMYaUIg32Orq5jUfLwW6q7Gg3VXZTZcHYrCoXvbjNX7uZ-r8lf9xk4PUJoDy7X46iTejII_UuZiu2D-7_-W_-KcfJeYft9IOOlMawRp-tWG6TsGC_bMuy7QqXAMLkad0Av8C5tw</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Haverkamp, Margje H</creator><creator>van de Vosse, Esther</creator><creator>van Dissel, Jaap T</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20140101</creationdate><title>Nontuberculous mycobacterial infections in children with inborn errors of the immune system</title><author>Haverkamp, Margje H ; van de Vosse, Esther ; van Dissel, Jaap T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-5c2df6e4fd7c679c92806b8979daca50c9951b9a40e927d90ce1110041cf691c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Immunotherapy - methods</topic><topic>Indexing in process</topic><topic>Infectious Disease</topic><topic>Interferon-gamma - therapeutic use</topic><topic>MSMD</topic><topic>Mutation</topic><topic>Mycobacterial infection</topic><topic>Mycobacterium</topic><topic>Mycobacterium Infections, Nontuberculous - complications</topic><topic>Mycobacterium Infections, Nontuberculous - epidemiology</topic><topic>Mycobacterium Infections, Nontuberculous - genetics</topic><topic>Mycobacterium Infections, Nontuberculous - immunology</topic><topic>Mycobacterium Infections, Nontuberculous - therapy</topic><topic>Nontuberculous Mycobacteria - isolation &amp; purification</topic><topic>Salmonella</topic><topic>Salmonella - isolation &amp; purification</topic><topic>Salmonella Infections - epidemiology</topic><topic>Salmonella Infections - genetics</topic><topic>Salmonella Infections - immunology</topic><topic>Salmonella Infections - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haverkamp, Margje H</creatorcontrib><creatorcontrib>van de Vosse, Esther</creatorcontrib><creatorcontrib>van Dissel, Jaap T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>The Journal of infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haverkamp, Margje H</au><au>van de Vosse, Esther</au><au>van Dissel, Jaap T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nontuberculous mycobacterial infections in children with inborn errors of the immune system</atitle><jtitle>The Journal of infection</jtitle><addtitle>J Infect</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>68</volume><spage>S134</spage><epage>S150</epage><pages>S134-S150</pages><issn>0163-4453</issn><eissn>1532-2742</eissn><abstract>Summary Severe mycobacterial disease is mostly confined to patients who are immunocompromized either by acquired or inherited causes. One such genetic disorder is Mendelian Susceptibility to Mycobacterial Disease (MSMD), a hot topic within the field of primary immunodeficiency. This single gene disorder is characterized by isolated infection with mycobacteria or Salmonella due to a defect in the type-1 cytokine response. In the last two decades, ten genes have been labeled as causing MSMD when they harbor germline mutations, namely IL12B , IL12RB1 , IFNGR1 , IFNGR2 , STAT1 , IKBKG , CYBB , TYK2 , IRF8 and ISG15 . The mutations lead to either insufficient production of IFN-γ, or to an insufficient response to the cytokine. Current treatment options include recombinant IFN-γ and hematologic stem cell transplantation (HSCT). In the future, gene therapy, antisense-mediated exon skipping and chemical intervention in glycosylation problems may become successful alternatives. Furthermore, it is likely that many new candidate genes and pathways crucial for mycobacterial immunity will be identified.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>24119826</pmid><doi>10.1016/j.jinf.2013.09.024</doi></addata></record>
fulltext fulltext
identifier ISSN: 0163-4453
ispartof The Journal of infection, 2014-01, Vol.68, p.S134-S150
issn 0163-4453
1532-2742
language eng
recordid cdi_proquest_miscellaneous_1540221039
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Child
Child, Preschool
Children
Hematopoietic Stem Cell Transplantation
Humans
Immunotherapy - methods
Indexing in process
Infectious Disease
Interferon-gamma - therapeutic use
MSMD
Mutation
Mycobacterial infection
Mycobacterium
Mycobacterium Infections, Nontuberculous - complications
Mycobacterium Infections, Nontuberculous - epidemiology
Mycobacterium Infections, Nontuberculous - genetics
Mycobacterium Infections, Nontuberculous - immunology
Mycobacterium Infections, Nontuberculous - therapy
Nontuberculous Mycobacteria - isolation & purification
Salmonella
Salmonella - isolation & purification
Salmonella Infections - epidemiology
Salmonella Infections - genetics
Salmonella Infections - immunology
Salmonella Infections - therapy
title Nontuberculous mycobacterial infections in children with inborn errors of the immune system
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A05%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nontuberculous%20mycobacterial%20infections%20in%20children%20with%20inborn%20errors%20of%20the%20immune%20system&rft.jtitle=The%20Journal%20of%20infection&rft.au=Haverkamp,%20Margje%20H&rft.date=2014-01-01&rft.volume=68&rft.spage=S134&rft.epage=S150&rft.pages=S134-S150&rft.issn=0163-4453&rft.eissn=1532-2742&rft_id=info:doi/10.1016/j.jinf.2013.09.024&rft_dat=%3Cproquest_cross%3E1490730862%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490730862&rft_id=info:pmid/24119826&rft_els_id=1_s2_0_S0163445313002910&rfr_iscdi=true